Logo
Make a donation
Make a donation

International symposium

...

2024 Symposium

1st

symposium organized by the Leukemia Institute in 2024

+400

attendees

+25

speakers

Day 1

  • Hugues de Thé, in presence of institutions representative
  • Andreas Trumpp – Therapy response and resistance of AML stem cells to Venetoclax
  • Andrew Lane – Targetable leukemia dependency on noncanonical PI3Ky signaling
  • Alexandre Puissant – Overcoming therapy resistance in acute myeloid leukemia
  • Nina Cabezas – Regulation of hematopoietic stem cell dormancy
  • Lina Benajiba – Unmasking myeloproliferative neoplasms transformation paths
  • Clemens Schmitt – AML state-switched
  • Marc Raaijmakers – Deconstructing niche contributions to disease pathogenesis and drug resistance in AML
  • Diana Passaro – 3D humanized models reveal novel spatial features of the leukemia microenvironment
  • David Michonneau – Lessons from azithromycin after allo-HSCT: how an antibiotic can promote relapse by disrupting immune and metabolic networks
  • Jacqueline Dubow (patient representative) – Quality of life matters: A Patient Perspective
  • Courtney DiNardo – AML therapy in 2024: increasingly individualized approaches
  • Olivier Kosmider – VEXAS syndrome in 2024
  • Régis Peffault de Latour – Paroxysmal nocturnal hemoglobinuria as an original
    non-malignant clonal expansion modulated by complement

Day 2

  • Lars Velten – Tracking human hematopoietic stem cell clones in health and disease
  • Emmanuelle Clappier – Genomic and clinical heterogeneity within adult acute
    lymphoblastic leukemia
  • Guillaume Andrieu – From metabolic vulnerabilities to targeted therapies in leukemia
  • Anindita Roy – Developmental origins of childhood leukemia: why does it matter ?
  • Timothy Ley – AML: Lessons from the genome
  • Ruud Delwel – Targeting evil enhancers and genes in AML
  • Raphael Itzykson – Targeting cystine import in AML
  • Keisuke Ito – Mitochondrial contributions to hematopoietic homeostasis
    and the pathogenesis of hematological disorders
  • Bethan Psaila – Targeting microenvironmental drivers of blood malignancies
  • Lionel Adès – Any crosstalk in the treatment of AML and HR-MDS
  • Marie Sebert – Clonal evolution of genetic predisposition to hematological malignancies
  • Domitille Rerolle – Pml unravels new insights into the bases of AML chemotherapy response
  • Paresh Vyas – Clonal Haemopoiesis: stem cell dynamics and stem cell response
    to inflammation